Benzinga
Goldman Sachs calls Minimed Group a compelling play on the diabetes market and a potentially profitable stock, with a target price of $24. MiniMed produces insulin pump platforms and continuous glucose monitoring technologies, and recently gained FDA approval for its next-generation insulin pump. The global diabetes market is expected to grow significantly, making MiniMed a promising investment opportunity. Importance Rank: 1 read more
Go to News Site